PLX Related FDA
-
Protalix Bio (PLX) Treats First Patient in PRX-112 Phase I
-
Pfizer (PFE), Protalix (PTX) UPLYSO Receives Approval in Brazil
-
Protalix BioTherapeutics (PLX) to Present Data on ELELYSO
-
Protalix (PLX) Enters ELELYSO Development Agreement w/ Pfizer (PFE)
-
Pfizer (PFE),Protalix (PLX) Report Taliglucerase Alfa Denied Marketing Approval by EC
-
Protalix Bio (PLX) Gets Elelyso Marketing Authorization in Israel
-
Protalix (PLX) Gets FDA Okay for PRX-102 Phase I/II Study of Fabry Disease
-
Protalix BioTherapeutics (PLX) Reports Encouraging Data from Taliglucerase Alfa in Type 1 Gaucher Disease
-
Data on Protalix's (PLX) ELELYSO to be Presented at 10th Annual European Working Group on Gaucher Disease Meeting
-
Protalix BioTherapeutics (PLX) Hit as EMA CHMP Denies MAA for Taliglucerase Alfa
-
Pfizer (PFE), Protalix (PLX) Say Taliglucerase Alfa MAA Not Approved by EMA CHMP
-
Protalix (PLX) Gets $25M Milestone from Pfizer in FDA Approval of ELELYSO as Treatment of Type 1 Gaucher
-
Protalix (PLX) Shares Jump Following FDA Approval of ELELYSO, Co. to Host Call at 8am ET Wednesday
-
FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
-
Traders Eye Protalix BioTherapeutics (PLX) Ahead of FDA PDUFA Date
-
UPDATE - Auriga Downgraded Protalix BioTherapeutics (PLX) to Hold; Odds of FDA Approval Are Difficult to Gauge
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential
-
Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months
-
FDA Extends PDUFA Date for Protalix's (PLX) Taliglucerase Alfa NDA
-
Protalix (PLX) Reports Presentation of PRX-105 Research on Striatum Splicing Patterns
-
Canaccord Genuity on Life Sciences/Biotechnology: FDA �Flexibility� May Add To Advantages of Orphan Drugs in Today's Market
-
Protalix (PLX) Reports Publication of Encouraging Data from Taliglucerase Phase III in Gaucher Disease
-
Protalix (PLX) Says FDA Accepts Resubmission of CRL for Taliglucerase Alfa; Sets Feb. 1 as PDUFA Date
-
Protalix (PLX) Submits Reply to Taliglucerase Alfa Response Letter from FDA
-
Protalix (PLX) Receives FDA CRL On Taliglucerase
-
Protalix BioTherapeutics (PLX) Lower Ahead of Tomorrow's PDUFA Date
-
Canaccord Adams Sees Protalix BioTherapeutics (PLX) FDA Approval Early
-
Protalix (PLX) Updates on PRX-102 and Gaucher Treatment GCD
-
Protalix BioTherapeutics (PLX) Completes Patient Switch from Cerezyme to Taliglucerase Alfa in Gaucher Study
-
Brazil To Produce Pfizer/Protalix Gaucher Disease Drug In $730 Million Deal
-
Protalix (PLX) Discloses $30M Pfizer Taliglucerase Alfa Supply Agreement In Latin American
-
Protalix BioTherapeutics (PLX) NDA for Taliglucerase Alfa Accepted for Review by U.S. FDA
-
Protalix BioTherapeutics (PLX) Submits Validation Data to FDA on Taliglucerase Alfa Manufacturing
-
Protalix BioTherapeutics (PLX) Announces Commencement of PRX-105 Phase I
-
Protalix BioThera (PLX) to Supply U.S. FDA with Additional Data Tied to Taliglucerase Alfa NDA
-
Protalix (PLX) Gets Orphan Drug Recommendation on Taliglucerase Alfa
-
Protalix BioTherapeutics (PLX) Taliglucerase Alfa Gets Recommendation from EMEA (PFE)
-
Protalix (PLX) Completes NDA Submission for taliglucerase alfa
-
Protalix (PLX) Sells-Off On Pfizer News, As Fast Money Disappointed In No Takeover
-
Protalix (PLX) Enters Deal With Pfizer (PFE) To Develop Gaucher's Disease Treatment
-
Protalix (PLX) Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease
-
FDA Grants Protalix (PLX) Orphan Drug Designation for prGCD
-
Protalix (PLX) Receives FDA Fast Track Designation for prGCD
-
Protalix BioTherapeutics (PLX) Announces FDA Approval of Treatment Protocol for prGCD
-
Protalix BioTherapeutics (PLX) Holds Pre-NDA Meeting with FDA for prGCD
-
Protalix (PLX) Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD
-
Protalix BioTherapeutics (PLX) Receives Special Protocol Assessment Approval from FDA for its Phase III Clinical Study of prGCD
-
Protalix BioTherapeutics (PLX) Receives FDA Approval to Begin Phase III Clinical Trials of prGCD
Back to PLX Stock Lookup
